JUMPCAN(SH:600566)2023-04-09 16:00Financial Performance - The company achieved operating revenue of CNY 8,996,366,979.29 in 2022, representing a 17.90% increase compared to CNY 7,630,510,000.18 in 2021[16]. - Net profit attributable to shareholders reached CNY 2,170,754,633.98, up 26.27% from CNY 1,719,175,931.11 in the previous year[16]. - The net profit after deducting non-recurring gains and losses was CNY 2,028,590,799.57, reflecting a 30.30% increase from CNY 1,556,880,008.39 in 2021[16]. - The company reported a net cash flow from operating activities of CNY 2,620,832,879.02, which is a 38.35% increase compared to CNY 1,894,329,392.98 in 2021[16]. - Basic earnings per share increased to CNY 2.44, a growth of 25.77% from CNY 1.94 in the previous year[17]. - The diluted earnings per share rose to CNY 2.39, marking a 25.13% increase from CNY 1.91 in 2021[17]. - The company maintained a weighted average return on equity of 21.91%, up from 20.46% in the previous year[17]. - The total assets of the company reached CNY 14,981,202,241.23 at the end of 2022, a 23.49% increase from CNY 12,131,036,777.90 at the end of 2021[16]. Dividend and Share Capital - The company plans to distribute a cash dividend of 8.80 CNY per 10 shares, totaling approximately 811.20 million CNY for the year 2022[3]. - The total share capital as of December 31, 2022, is 921,822,160 shares[3]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[2]. - There are no significant risks that could materially affect the company's operations during the reporting period[5]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[4]. - The company has not violated any decision-making procedures for providing guarantees[4]. Risk Management - The management has outlined potential risks that may adversely impact future development strategies and operational goals[5]. - The company emphasizes the importance of investment risk awareness for investors regarding forward-looking statements[4]. Research and Development - The company invested CNY 553,303,050.84 in R&D, which is a 5.70% increase from the previous year[34]. - The company obtained five invention patents during the reporting period, enhancing its R&D capabilities[24]. - The company has three projects in the consistency evaluation research phase and has submitted 15 projects for production approval[24]. - The company plans to continue increasing R&D investment and actively recruit high-end R&D talent to enhance its product line[73]. Product Development and Market Strategy - The company plans to continue expanding its product offerings, with significant sales growth in products like Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules[17]. - The company is actively expanding its product offerings, with several new drugs under development, including those for epilepsy and chronic kidney disease[63][65]. - The company aims to enhance its product line and improve sustainable development and profitability through increased R&D investment and optimized sales channels[26]. - The company will closely monitor the implementation of DRG/DIP payment pilot programs to adjust product strategies accordingly[27]. Sales and Marketing - The company expanded its sales channels through partnerships with internet hospitals and digital marketing strategies[25]. - The company’s sales strategy focuses on academic promotion and channel distribution, enhancing its market penetration capabilities[32]. - The company is enhancing its talent development programs to improve employee skills and strengthen its core competitiveness[90]. Environmental Compliance - The company has maintained a focus on environmental compliance and has not reported any exceedances in pollutant emissions during the reporting period[142]. - The company has established a comprehensive wastewater treatment station with a daily processing capacity of 2000 tons, operating continuously[148]. - The company reported a maximum ammonia emission of 0.50 mg/m³ from the wastewater treatment station, below the limit of 20 mg/m³[146]. Corporate Governance - The company achieved complete independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations[95]. - The company held its 2021 Annual General Meeting on May 9, 2022, where eight resolutions were approved, including the full annual report and profit distribution plan for 2021[96]. - The company plans to continue the current board and supervisory committee until the new elections are completed, ensuring stability in governance[100]. Shareholder Relations - The company has established a shareholder return plan for 2020-2022, stipulating that cash dividends should not be less than 30% of the average distributable profit over the last three years, with specific conditions for higher percentages based on the company's development stage[124]. - The company’s profit distribution plan requires a two-thirds majority approval from shareholders present at the general meeting[124]. Financial Management - The company utilized idle funds to invest in wealth management products, with a total amount of 1,115,000,000 RMB from raised funds and 1,700,000,000 RMB from self-owned funds[176]. - The outstanding balance of wealth management products as of December 31, 2022, was 1,661,000,000 RMB[177]. - The company has a diversified investment approach, utilizing both raised and self-owned funds for wealth management[176]. Employee Management - The company employed a total of 5,025 staff, with 2,318 in production, 1,081 in sales, 709 in technical roles, 140 in finance, and 777 in administration[120]. - The company has established a training program focusing on management, marketing, technical skills, and operational knowledge to enhance employee capabilities[122]. Strategic Initiatives - The company plans to enhance marketing management and optimize sales channels to improve profitability[79]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[102].